Brain metabolism changes in middle‐aged asymptomatic APOE‐ε4 carriers. The PESA Study

Apolipoprotein E (APOE) is the major genetic risk factor for late‐onset Alzheimer’s disease (AD) and is implicated in cardiovascular disease. TheAPOE‐ε4 allele is associated with brain hypometabolism in AD, mild cognitive impairment (MCI) (Mosconi et al. Neurology 2004) and in cognitively unimpaired middle‐aged individuals (Reiman et al. NEJM 1996). Greater longitudinal decreases in brain metabolism were reported in APOE‐ε4 carriers with MCI (Paranjpe et al. Neuroimage Clin 2019), but studies on brain metabolism longitudinal changes in unimpaired middle‐aged APOE‐ε4 carriers are scarce and with relatively small sample sizes (Reiman et al. PNAS 2001). The Progression of Early Subclinical Atherosclerosis (PESA) study is a longitudinal study following >4000 asymptomatic middle‐aged subjects deeply screened for cardiovascular risk factors (CVRFs) (Fernandez‐Ortiz et al. AHJ 2013). Individuals with the highest burden of atherosclerosis underwent FDG‐PET at baseline and CVRFs were associated with hypometabolism in AD regions (Cortés‐Canteli & Gispert et al. JACC 2021). Those individuals underwent a 6‐year follow‐up FDG‐PET. Here, we investigate the effect of APOE genotype on brain metabolism progression in middle‐aged asymptomatic individuals.